Adam Frymoyer

Adam Frymoyer

Stanford University - Stanford / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 1654262
person_outline Adam Frymoyer's MOST POPULAR ARTICLES
1-) Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH‐dependent solubility the Achilles heel of targeted therapy?NR Budha, A Frymoyer, GS Smelick, JY Jin, MR Yago, MJ Dresser, ...Clinical Pharmacology & Therapeutics 92 (2), 203-213, 20123122012
2-) 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancerN Nagy, HF Kuipers, AR Frymoyer, HD Ishak, JB Bollyky, TN Wight, ...Frontiers in immunology 6, 123, 20152372015
3-) Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug–drug interaction potential for molecular targeted agents in clinical developmentGS Smelick, TP Heffron, L Chu, B Dean, DA West, SL DuVall, BL Lum, ...Molecular pharmaceutics 10 (11), 4055-4062, 20131702013
4-) Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequateA Frymoyer, AL Hersh, LZ Benet, BJ GuglielmoThe Pediatric infectious disease journal 28 (5), 398-402, 20091772009
5-) Association between vancomycin trough concentration and area under the concentration-time curve in neonatesA Frymoyer, AL Hersh, MH El-Komy, S Gaskari, F Su, DR Drover, ...Antimicrobial agents and chemotherapy 58 (11), 6454-6461, 20141482014